



Changing lives with cell therapy

Australia Biotech Invest 2013


Dr Andrea Grant, Managing Director

ASX:LCT | OTCQX: LVCLY | www.lctglobal.com |  LCTglobal

Cell therapy – the fourth pillar of healthcare



Stem cell therapies require substantial genetic manipulation of cells



Primary cells from disease-free herd




Insulin: Type I diabetes

Heparin: Blood thinning


Factor VI: Blood clotting

Tissue grafts & wound healing

Encapsulation = No immunosuppressants




First product in clinical development



DIABECCELL®

BREAKTHROUGH IN **TYPE 1 DIABETES**

Type I diabetes



Auto-immune destruction of insulin producing islets

Encapsulated pig islets replace glucose regulation

No toxic immunosuppressants

Progress towards market



Trial	Endpoint	Country	# patients	Status
DIA-04	Safety	Russia	10	Complete
DIA-06	Safety & dose finding	NZ	16	Complete
DIA-09	Safety & dose finding	Argentina	8	Results expected Oct 2013
DIA-14	Efficacy	NZ, Aus, Singapore	30-60	In preparation

JV partnership with top- tier Japanese Pharma



Formed 2011

50% control=50% profits

OPF invested AU\$25m to date

JV funds clinical development

Potential for additional AU\$20m







Clinical development de-risked




Juvenile Diabetes Cure Alliance



“Of 332 projects in human clinical trials, only 6 target a type 1 diabetes practical cure” *www.thejdca.org*

Project Name	Description	Location
DIABECCELL	Transplanted porcine islets that are micro-encapsulated	
Monolayer Cellular Device	A beta cell encapsulation approach that uses human islets	
ATG/GCSF	Drug combination aimed at stopping both the autoimmune attack and stimulating growth of beta cells	
Sitagliptin/ Lansoprazole	Drug combination aimed at stopping both the autoimmune attack and stimulating growth of beta cells	
BCG	Drug that kills disease-causing autoimmune cells and restores pancreatic beta-cell function through regeneration	
Stem Cell Educator	An individual's blood is treated with stem cells which has the effect of reversing autoimmunity and stimulating beta cell growth	


Second product in clinical development



NTCELL[®]

NEW HOPE IN **PARKINSON'S DISEASE**

Loss of dopamine neurons



**No
Parkinson's**



Parkinson's

Parkinson's disease


"The saddest of all diseases"



Choroid plexus = growth factor factory





100's of growth factors



Nerve regeneration
Stem cell differentiation
Protection from cell death


>50% improvement in primate models




Control



NT



NTCELL for Parkinson's Phase I underway



4 patients – SAFETY study

First implant safely completed Sept 2013

Provided safety demonstrated – we will aim for fast track/breakthrough designation with FDA


NTCELL co-development partnership in NTCELL



Up to \$5m option fee
OPF funds Phase I clinical trial
Clinical development de-risked



LCT is developing NTCELL for a range of degenerative disorders



Invest in a leader



Diversify your cell therapy portfolios

Advanced in clinic

Diseases with high unmet need

Global pharma partner

SAFE HARBOR STATEMENT



This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.